Clinical pharmacists participating in the pharmaceutical care of a patient with low-risk gestational trophoblastic neoplasia_West China Medical Journal

Authors：

 SUN Jiajing ¹ , CHEN Li ² , WU Wen ³ , FAN Wangdong ⁴

1. Department of Pharmacy, Dujiangyan People’s Hospital, Dujiangyan, Sichuan 611830, P. R. China;
2. Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
3. Department of Pharmacy, Leshan People’s Hospital, Leshan, Sichuan 614000, P. R. China;
4. Department of Pharmacy, West China Fourth Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

SUN Jiajing, Email: 178804608@qq.com

Keywords：

Clinical pharmacist; Gestational trophoblastic neoplasia; Pharmaceutical care; Work practice

DOI：

10.7507/1002-0179.201603228

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the way of clinical pharmacists participating in formulating the chemotherapy regimen for cancer and pharmaceutical monitoring, through the practice of drug treatment in a patient with gestational trophoblastic neoplasia. Methods Clinical pharmacists participated in the treatment of one patient with low-risk gestational trophoblastic neoplasia in gynecological chemotherapy ward, from the first chemotherapy in January 2015 to the clinical cure. The countermeasures included designating chemotherapy regimen, monitoring clinical efficacy and adverse reactions, changing the chemotherapy regimen in time when the curative effect was poor, and coping with adverse reactions. Results Physicians adopted the suggestions from clinical pharmacists and the patient was clinically cured after standardized treatment. Conclusion Pharmaceutical care by clinical pharmacists can assist clinicians to ensure the safety and effectiveness of drug use.

Citation： SUN Jiajing, CHEN Li, WU Wen, FAN Wangdong. Clinical pharmacists participating in the pharmaceutical care of a patient with low-risk gestational trophoblastic neoplasia. West China Medical Journal, 2018, 33(4): 427-430. doi: 10.7507/1002-0179.201603228 Copy

1.	沈铿, 崔恒, 丰有吉. 常见妇科恶性肿瘤诊治指南. 4 版. 北京: 人民卫生出版社, 2014: 115-135.
2.	Morgan JM, Lurain JR. Gestatinal trophoblastic neoplasia: an update. Curr Oncol Rep, 2008, 10(6): 497-504.
3.	Smith HO, Wiggins C, Verschraegen CF, et al. Changing trends in gestational trophoblastic disease. J Reprod Med, 2006, 51(10): 777-784.
4.	Cole LA, Butler SA, Khanlian SA, et al. Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia. Gynecol Oncol, 2006, 102(2): 151-159.
5.	朱晓旭, 钱建华, 掌佩文, 等. 不同 HCG 水平妊娠滋养细胞肿瘤的临床特征和治疗分析. 浙江医学, 2016, 38(9): 611-613.
6.	Lertkhachonsuk AA, Israngura N, Wilailak S, et al. Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial. Int J Gynecol Cancer, 2009, 19(5): 985-988.
7.	Deng LY, Zhang J, Wu TX, et al. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev, 2013(1): CD005196.
8.	Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol, 2005, 97(2): 618-623.
9.	Yarandi F, Eftekhar Z, Shojaei H, et al. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. Int J Gynaecol Obstet, 2008, 103(1): 33-37.
10.	Osborne RJ, Filiaci V, Schink JC, et al. Phase Ⅲ trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol, 2011, 29(7): 825-831.
11.	Gilani MM, Yarandi F, Eftekhar Z, et al. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Aust N Z J Obstet Gynaecol, 2005, 45(2): 161-164.
12.	Alazzam M, Tidy J, Hancock BW, et al. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev, 2012(7): CD007102.
13.	Osborne R, Gerulath A. What is the best regimen for low-risk gestational trophoblastic neoplasia. A review. J Reprod Med, 2004, 49(8): 602-616.
14.	Mcneish IA, Strickland S, Holden L, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol, 2002, 20(7): 1838-1844.
15.	刘建军, 崔林, 张志胜. 重组人粒细胞集落刺激因子对化疗后粒细胞下降的疗效观察. 肿瘤研究与临床, 2006, 18(12): 848-849.

1. 沈铿, 崔恒, 丰有吉. 常见妇科恶性肿瘤诊治指南. 4 版. 北京: 人民卫生出版社, 2014: 115-135.
2. Morgan JM, Lurain JR. Gestatinal trophoblastic neoplasia: an update. Curr Oncol Rep, 2008, 10(6): 497-504.
3. Smith HO, Wiggins C, Verschraegen CF, et al. Changing trends in gestational trophoblastic disease. J Reprod Med, 2006, 51(10): 777-784.
4. Cole LA, Butler SA, Khanlian SA, et al. Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia. Gynecol Oncol, 2006, 102(2): 151-159.
5. 朱晓旭, 钱建华, 掌佩文, 等. 不同 HCG 水平妊娠滋养细胞肿瘤的临床特征和治疗分析. 浙江医学, 2016, 38(9): 611-613.
6. Lertkhachonsuk AA, Israngura N, Wilailak S, et al. Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial. Int J Gynecol Cancer, 2009, 19(5): 985-988.
7. Deng LY, Zhang J, Wu TX, et al. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev, 2013(1): CD005196.
8. Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol, 2005, 97(2): 618-623.
9. Yarandi F, Eftekhar Z, Shojaei H, et al. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. Int J Gynaecol Obstet, 2008, 103(1): 33-37.
10. Osborne RJ, Filiaci V, Schink JC, et al. Phase Ⅲ trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol, 2011, 29(7): 825-831.
11. Gilani MM, Yarandi F, Eftekhar Z, et al. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Aust N Z J Obstet Gynaecol, 2005, 45(2): 161-164.
12. Alazzam M, Tidy J, Hancock BW, et al. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev, 2012(7): CD007102.
13. Osborne R, Gerulath A. What is the best regimen for low-risk gestational trophoblastic neoplasia. A review. J Reprod Med, 2004, 49(8): 602-616.
14. Mcneish IA, Strickland S, Holden L, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol, 2002, 20(7): 1838-1844.
15. 刘建军, 崔林, 张志胜. 重组人粒细胞集落刺激因子对化疗后粒细胞下降的疗效观察. 肿瘤研究与临床, 2006, 18(12): 848-849.

West China Medical Journal

Clinical pharmacists participating in the pharmaceutical care of a patient with low-risk gestational trophoblastic neoplasia

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content